Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, filed on Thursday with the SEC to raise up to $86 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2015 and booked $4 million in collaboration revenue for the 12 months ended September 30, 2018. It plans to list on the Nasdaq under the symbol HARP. Harpoon Therapeutics filed confidentially on October 24, 2018. Citi and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
